HRP20230154T1 - Anti-met fab-fc za liječenje tumora i/ili metastaza - Google Patents
Anti-met fab-fc za liječenje tumora i/ili metastaza Download PDFInfo
- Publication number
- HRP20230154T1 HRP20230154T1 HRP20230154TT HRP20230154T HRP20230154T1 HR P20230154 T1 HRP20230154 T1 HR P20230154T1 HR P20230154T T HRP20230154T T HR P20230154TT HR P20230154 T HRP20230154 T HR P20230154T HR P20230154 T1 HRP20230154 T1 HR P20230154T1
- Authority
- HR
- Croatia
- Prior art keywords
- human
- domain
- antibody fragment
- met
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009282A IT201800009282A1 (it) | 2018-10-09 | 2018-10-09 | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| PCT/EP2019/077116 WO2020074459A1 (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
| EP19808675.3A EP3864050B1 (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230154T1 true HRP20230154T1 (hr) | 2023-03-31 |
Family
ID=65010823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230154TT HRP20230154T1 (hr) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc za liječenje tumora i/ili metastaza |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12209129B2 (enExample) |
| EP (2) | EP3864050B1 (enExample) |
| JP (1) | JP7371093B2 (enExample) |
| KR (2) | KR20250078600A (enExample) |
| CN (2) | CN119587692A (enExample) |
| AU (2) | AU2019358417B2 (enExample) |
| CA (1) | CA3115582A1 (enExample) |
| CY (1) | CY1125831T1 (enExample) |
| DK (1) | DK3864050T5 (enExample) |
| ES (1) | ES2938714T3 (enExample) |
| FI (1) | FI3864050T3 (enExample) |
| HR (1) | HRP20230154T1 (enExample) |
| HU (1) | HUE060843T2 (enExample) |
| IL (1) | IL282033B2 (enExample) |
| IT (1) | IT201800009282A1 (enExample) |
| LT (1) | LT3864050T (enExample) |
| PL (1) | PL3864050T3 (enExample) |
| PT (1) | PT3864050T (enExample) |
| RS (1) | RS63960B1 (enExample) |
| SG (1) | SG11202103575RA (enExample) |
| SI (1) | SI3864050T1 (enExample) |
| SM (1) | SMT202300053T1 (enExample) |
| WO (1) | WO2020074459A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260019463A (ko) | 2023-06-01 | 2026-02-10 | 피에르 파브르 메디카먼트 | 종양 및 전이의 치료를 위한 침묵화된 항체 기반의 항-met 구조물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1718677E (pt) * | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| ES2368864T3 (es) | 2006-02-06 | 2011-11-23 | Metheresis Translational Research Sa | Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. |
| BRPI0710971A2 (pt) * | 2006-04-28 | 2011-05-31 | Esbatech Ag | anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk |
| EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| DK2786762T3 (da) * | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| RU2583270C2 (ru) * | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| PL2500036T3 (pl) * | 2011-03-18 | 2014-10-31 | Metheresis Translational Res Sa | Inhibitory met do zwiększania skuteczności radioterapii |
| MX2013011363A (es) * | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
| CA2843158A1 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| SG11201402485UA (en) | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| CA3050085A1 (en) * | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
-
2018
- 2018-10-09 IT IT102018000009282A patent/IT201800009282A1/it unknown
-
2019
- 2019-10-07 JP JP2021518891A patent/JP7371093B2/ja active Active
- 2019-10-07 US US17/283,482 patent/US12209129B2/en active Active
- 2019-10-07 DK DK19808675.3T patent/DK3864050T5/da active
- 2019-10-07 CN CN202411779087.7A patent/CN119587692A/zh active Pending
- 2019-10-07 RS RS20230107A patent/RS63960B1/sr unknown
- 2019-10-07 LT LTEPPCT/EP2019/077116T patent/LT3864050T/lt unknown
- 2019-10-07 EP EP19808675.3A patent/EP3864050B1/en active Active
- 2019-10-07 KR KR1020257016475A patent/KR20250078600A/ko active Pending
- 2019-10-07 CA CA3115582A patent/CA3115582A1/en active Pending
- 2019-10-07 SG SG11202103575RA patent/SG11202103575RA/en unknown
- 2019-10-07 IL IL282033A patent/IL282033B2/en unknown
- 2019-10-07 AU AU2019358417A patent/AU2019358417B2/en active Active
- 2019-10-07 SI SI201930456T patent/SI3864050T1/sl unknown
- 2019-10-07 ES ES19808675T patent/ES2938714T3/es active Active
- 2019-10-07 KR KR1020217013513A patent/KR102814490B1/ko active Active
- 2019-10-07 PT PT198086753T patent/PT3864050T/pt unknown
- 2019-10-07 WO PCT/EP2019/077116 patent/WO2020074459A1/en not_active Ceased
- 2019-10-07 CN CN201980080611.2A patent/CN113330032B/zh active Active
- 2019-10-07 PL PL19808675.3T patent/PL3864050T3/pl unknown
- 2019-10-07 SM SM20230053T patent/SMT202300053T1/it unknown
- 2019-10-07 FI FIEP19808675.3T patent/FI3864050T3/fi active
- 2019-10-07 HU HUE19808675A patent/HUE060843T2/hu unknown
- 2019-10-07 EP EP22206743.1A patent/EP4194469A1/en active Pending
- 2019-10-07 HR HRP20230154TT patent/HRP20230154T1/hr unknown
-
2023
- 2023-02-09 CY CY20231100073T patent/CY1125831T1/el unknown
-
2024
- 2024-12-09 US US18/973,463 patent/US20250101115A1/en active Pending
-
2026
- 2026-02-26 AU AU2026201438A patent/AU2026201438A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022218544B2 (en) | Hetero-dimeric multi-specific antibody format | |
| CN110305210B (zh) | 新型抗体分子、其制备方法及其用途 | |
| CN101445559B (zh) | 三聚体可溶抗体与其产生及使用的方法 | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| CN107922491B (zh) | 多价和多特异性结合dr5的融合蛋白 | |
| JP6853250B2 (ja) | 抗体の挿入可能な可変フラグメント及びｎｋｇ２ｄリガンドの改変されたａ１−ａ２ドメイン、及び非天然のｎｋｇ２ｄ受容体に結合する非天然のｎｋｇ２ｄリガンド | |
| JP6385357B2 (ja) | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 | |
| CN110520445B (zh) | 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| JP2012515556A5 (enExample) | ||
| IL276286B2 (en) | FC variants with improved binding to FCRN and extended half-life | |
| CN113227134A (zh) | 抗体的Fc区变体 | |
| WO2019184909A1 (zh) | 新型抗体分子、其制备方法及其用途 | |
| AU2021390121A9 (en) | Anti-human b7-h3 antibody and application thereof | |
| JP2017509323A5 (enExample) | ||
| ME02653B (me) | Genski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena | |
| TW202233694A (zh) | 雙特異性抗體 | |
| CN117120478A (zh) | 一种抗原结合分子 | |
| HRP20230154T1 (hr) | Anti-met fab-fc za liječenje tumora i/ili metastaza | |
| US8207307B2 (en) | Antibodies against human CCN1 and uses thereof | |
| CN117264054B (zh) | 靶向il-6的纳米抗体、组合物、方法及用途 | |
| JP2022504392A5 (enExample) | ||
| HK40095576B (zh) | 双特异性抗体及其应用 | |
| HK40095576A (zh) | 双特异性抗体及其应用 | |
| CN121399164A (zh) | 双重转运体及使用方法 |